Overview
Title
To amend title 38, United States Code, to ensure that the Secretary of Veterans Affairs furnishes certain non-opioid pain medications to veterans, and for other purposes.
ELI5 AI
The bill H. R. 10396, or the "NOPAIN for Veterans Act," wants to make sure that veterans can get medicines that help with pain without using things that work like opioids. It makes the Veterans Affairs boss quickly add these non-opioid medicines to their list so veterans can use them.
Summary AI
The bill H. R. 10396, called the "NOPAIN for Veterans Act," proposes changes to the United States Code to ensure that veterans have access to non-opioid pain medications. It requires the Secretary of Veterans Affairs to quickly include eligible non-opioid pain medications in the VA's national formulary and drug standardization list after they receive specific approvals. The bill also ensures that no funds from the Cost of War Toxic Exposures Fund will be used for these changes, and it mandates implementation within 90 days of enactment.
Published
Keywords AI
Sources
Bill Statistics
Size
Language
Complexity
AnalysisAI
General Summary of the Bill
The bill, officially titled H. R. 10396, seeks to amend title 38 of the United States Code. Its primary aim is to ensure that the Secretary of Veterans Affairs provides veterans with certain non-opioid pain medications. Introduced by Representatives Landsman and Van Orden, the "NOPAIN for Veterans Act" mandates that new non-opioid pain management drugs, once approved and eligible for specific payment regulations, should be added to the Department of Veterans Affairs' (VA) National Formulary. This ensures that these alternatives to opioid pain relief are available to veterans.
Summary of Significant Issues
The bill has several areas that need careful consideration:
Ambiguity in Definition: The term "non-opioid pain management drug or biological product" is defined as one that does not act on the body's opioid receptors. However, this definition might be vague and open to interpretation, potentially complicating the implementation process.
Funding Concerns: It explicitly states that funds from the Cost of War Toxic Exposures Fund cannot be used for these changes. This raises the question of where the necessary funding will come from and whether it will be sufficient.
Oversight and Evaluation: There are no clear mechanisms for oversight or evaluation to ensure that the incorporation of these medications is managed efficiently. This lack could increase the risk of mismanagement or resource wastage.
Regulatory References: The bill mentions "successor regulation," but without specificity, this could lead to confusion or disputes over which regulations apply when determining payment eligibility.
Implementation Timeline: The Secretary of Veterans Affairs is required to implement these amendments within 90 days after the bill is enacted. This short timeframe could present feasibility challenges.
Potential Impact on the Public
Broadly speaking, the bill aims to benefit veterans by expanding their access to pain management options that do not involve opioids. This initiative could significantly impact veterans’ health outcomes by reducing dependency on opioids and potentially decreasing rates of addiction.
Impact on Specific Stakeholders
Veterans: The primary beneficiaries of the bill will be veterans who suffer from pain and may seek alternatives to opioid medications. Increasing access to non-opioid pain relief could enhance their quality of life and reduce the risk of addiction.
Department of Veterans Affairs: The VA will need to adapt quickly to these changes, considering the 90-day implementation requirement. This may strain their resources and processes, especially since no additional funding sources are clearly outlined.
Healthcare Providers: Providers working within the VA system might benefit from having a broader array of pain management tools at their disposal, enabling them to tailor treatments more specifically to each veteran’s needs.
Pharmaceutical Companies: Those developing non-opioid pain management drugs might see increased demand for their products as a result of this bill, incentivizing innovation in this area.
In summary, while the bill presents a well-meaning step toward addressing the opioid crisis among veterans, it carries with it several points that require further elaboration and support to ensure a smooth and effective implementation.
Issues
The definition of 'non-opioid pain management drug or biological product' in Section 2 may be ambiguous due to the phrase 'without acting upon the body’s opioid receptors,' which could lead to uncertainties about what qualifies and hinder the implementation of the bill.
The exclusion of funds from the Cost of War Toxic Exposures Fund in Section 2(b) raises concerns about alternative sources of funding for the implementation of the bill, potentially leading to financial strain or insufficient resources for execution.
The lack of oversight or evaluation mechanisms in Section 2 to ensure the effectiveness and efficiency of including non-opioid pain medications in the VA National Formulary presents risks of mismanagement or wastage of resources.
The reference to 'successor regulation' in Section 2(d) is vague, which could lead to legal disputes or uncertainty regarding the applicable regulations for payment eligibility.
The practicality and feasibility of implementing the required amendments within 90 days, as mandated in Section 2(c), could be challenging and may not allow sufficient time for thorough execution and integration into existing systems.
Sections
Sections are presented as they are annotated in the original legislative text. Any missing headers, numbers, or non-consecutive order is due to the original text.
1. Short title Read Opens in new tab
Summary AI
The section provides the short title of the Act, which can be referred to as the “NOPAIN for Veterans Act”.
2. Inclusion of certain non-opioid pain medications in the National Formulary of the Department of Veterans Affairs Read Opens in new tab
Summary AI
The bill section requires the Department of Veterans Affairs to include non-opioid pain medications in their National Formulary within one year of them becoming eligible for specific payments under Social Security and other regulations. Additionally, it specifies that no funds from the Cost of War Toxic Exposures Fund can be used to implement these changes, and mandates that the updates be in place within 90 days after the bill is enacted.